Intermittent fasting and GLP-1 drugs both cut how much you eat, so it is natural to wonder whether they stack.
The short answer is that nobody has tested the combination for weight loss. What does exist is clinical guidance, trials of fasting alone, and studies of people who fasted for Ramadan while on these drugs.
What the nutrition guidance says
A 2025 joint advisory on nutrition during GLP-1 treatment addresses fasting directly [1]. It opens with a risk: “Intermittent fasting may increase the risk of hypoglycemia in individuals with type 2 diabetes on hypoglycemic agents and those with type 1 diabetes.”
It then notes that many people fast without meaning to. They “may also practice unintended intermittent fasting, due to not being hungry.”
Its advice runs against long gaps. “Even when using intermittent fasting, individuals taking GLP-1s should be encouraged to consume meals at regular times of the day.”
It explains why. Long fasts without enough protein or variety “can lead to nutritional inadequacy, clinical nutrient deficiencies, loss of fat-free mass, and reduced resting energy expenditure.”
Its remedy is strength training, enough protein and calories, and varied, minimally processed food. The protein targets are in what to eat on semaglutide, and lean mass in GLP-1 muscle loss.
Does intermittent fasting work on its own?
That matters, because a combination can only add what each part brings. The TREAT trial tested 16:8 time-restricted eating in 116 adults with overweight or obesity [3].
One group ate only between noon and 8 pm. The other ate three meals across the day. Neither group was on a weight-loss drug, and the trial ran 12 weeks.
−0.94 kg
Weight change with 16:8 eating over 12 weeks
Lowe 2020
−0.68 kg
Weight change with three meals a day
Lowe 2020
P = .63
Difference between the groups (−0.26 kg), not significant
Lowe 2020
In a subgroup scanned in person, the fasting group lost more appendicular lean mass. The difference in lean mass index was −0.16 kg/m² (95% CI −0.27 to −0.05).
The authors concluded that time-restricted eating, “in the absence of other interventions, is not more effective in weight loss than eating throughout the day.”
Fasting while on a GLP-1 drug: the Ramadan studies
The only studies of people fasting daily while on these drugs come from Ramadan. Every one enrolled adults with type 2 diabetes, not people using the drugs for weight alone.
| Study | Design and size | Drug | Low blood sugar |
|---|---|---|---|
| LIRA-Ramadan 2016 | Randomized, open-label, versus a sulfonylurea | Liraglutide 1.8 mg daily | 2% (3 people) versus 11% (18 people) |
| Kamrul-Hasan 2025 | Meta-analysis, 4 studies, 754 people | Several GLP-1 drugs | Risk ratio 0.38 versus other drugs |
| O-SEMA-FAST 2025 | Observational, 257 people, 20 weeks | Oral semaglutide | 31.0% self-reported, none severe |
| Rahman 2026 | Observational, 109 people | Tirzepatide 2.5 mg weekly | None reported |
In the randomized trial, liraglutide gave similar short-term glucose control to a sulfonylurea during Ramadan [4]. Weight fell 0.54 kg more on liraglutide.
The meta-analysis found a 0.31-point larger fall in HbA1c and 2.0 kg more weight loss on GLP-1 drugs [5]. It also found higher risks of gastrointestinal side effects, nausea and vomiting.
Its authors call the evidence “limited” and ask for large multicenter trials. The comparison is against other diabetes drugs, not against the same drug without fasting.
The tirzepatide cohort was small and had no comparison group [7]. Mild stomach side effects affected about 12%, and no low blood sugar was reported.
Why low blood sugar comes up
The Wegovy label warns that the drug “lowers blood glucose and can cause hypoglycemia” [2]. The risk rises when it is used with insulin or a sulfonylurea.
That is the risk the advisory has in mind when it flags fasting in diabetes. If you take either kind of drug, ask your prescriber before adding a fasting schedule.
If fasting means skipping doses
Some people pause the weekly shot during a fast. The Wegovy label says that if two or more weekly doses in a row are missed, the dose should be built up again from a lower level [2].
The reason is to “reduce the risk of gastrointestinal adverse reactions.” A 2026 case report shows what can happen otherwise [8].
A 51-year-old woman stopped semaglutide 2.4 mg for five weeks during Ramadan. She restarted at the full dose. The next day she developed severe nausea, vomiting and diarrhea.
She needed intravenous fluids and electrolyte replacement, and spent four days in hospital. The authors advise against stopping for daytime fasting alone, and a slower restart after a long break.
One case sets no rate. Fluid loss on these drugs is covered in does Ozempic cause dehydration.
What has not been tested
A 2025 narrative review proposes a phased plan pairing GLP-1 drugs with structured fasting and high protein [9]. Its authors say the plan still needs validating “in randomized trials.”
One registered trial compares time-restricted eating and semaglutide or tirzepatide in men on hormone therapy for prostate cancer [10]. It tests them as separate arms, not together. Its estimated completion is 2028.
So whether fasting adds weight loss on top of a GLP-1 drug is unknown. Whether it costs extra lean mass is also unknown. The advisory’s regular-meals advice is the closest thing to guidance.
If you want to try a fasting schedule, raise it with your prescriber, especially if you have diabetes. This page is general information, not medical or dietary advice. Food choices on the drugs are in what to eat on tirzepatide.